Processa Pharmaceuticals, INC 8-K filings

Processa Pharmaceuticals presented new data at the AACR Annual Meeting 2024, highlighting positive results from its Phase 1b trial of NGC-Cap, a next-generation cancer drug.

Processa Pharmaceuticals CEO, George Ng, presented at the MedInvest Biotech + Pharma Investor Conference on April 3, 2024, discussing next-generation chemotherapy.

Processa Pharmaceuticals CEO, George Ng, presented at the Winter Wrap-Up MicroCap Rodeo Conference on February 20, 2024, with the presentation available on the company's website.

Processa Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on the Nasdaq Capital Market.

Processa Pharmaceuticals has successfully priced a $7 million public offering to fund the development of its next-generation chemotherapy drugs.

Processa Pharmaceuticals successfully completed the Phase 1b safety evaluation of its Next Generation Capecitabine (NGC-Cap) for advanced cancer, demonstrating improved tolerability and preliminary efficacy compared to standard capecitabine, leading to the selection of two dosage regimens for a Phase 2 trial in breast cancer.

Processa Pharmaceuticals will expand its Next Generation Capecitabine (NGC-Cap) program into advanced or metastatic breast cancer, with the FDA agreeing that existing data can support the Phase 2 trial design.

Processa Pharmaceuticals will implement a 1-for-20 reverse stock split effective January 22, 2024, to regain compliance with Nasdaq's minimum bid price requirement.